Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Cand

Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Cand

Agreement expands Mycovia’s commercialization that is global for VT-1161 to European countries, Latin America, Australia, Russia and Commonwealth of Independent States

Mycovia continues to rapidly develop VT-1161 as a possible first FDA-approved remedy for recurrent candidiasis that is vulvovaginal

DURHAM, N.C.–( COMPANY WIRE )–Mycovia Pharmaceuticals, Inc. today announced this has entered into a special permit and development and technology transfer agreement with Gedeon Richter Plc., located in Budapest, Hungary, to commercialize and produce VT-1161 in European countries, Latin America, Australia, Russia along with other CIS nations. VT-1161, a dental product that is antifungal, is in stage 3 medical studies for the remedy for Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that impacts almost 138 million females global every year.

“We are excited to partner with Gedeon Richter, a business with strong market leadership in women’s health, to develop and commercialize VT-1161, our prospective first FDA-approved treatment plan for RVVC,” said Patrick Jordan, CEO of Mycovia and Partner at NovaQuest Capital Management, which formed Mycovia in 2018 to advance VT-1161 in worldwide areas. “VT-1161 is well positioned to handle the requirements of the an incredible number of ladies who suffer with vexation, discomfort and psychological distress due to RVVC consequently they are searching for a treatment option that is new. ادامه خواندن “Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Cand”